TY - JOUR
T1 - Nudges for Privacy and Security: Understanding and Assisting Users' Choices Online ACM Reference Format
AU - Acquisti, Alessandro
AU - Komanduri, Saranga
AU - Analytics PEDRO GIOVANNI LEON, Civis
AU - de Mexico, Banco
AU - Schaub, Florian
AU - Wang, Yang
AU - Wilson, Shomir
AU - Balebako, R
AU - Adjerid, Idris
AU - Balebako, Rebecca
AU - Brandimarte, Laura
AU - Faith Cranor, Lorrie
AU - Giovanni Leon, Pedro
AU - Sadeh, Norman
AU - Sleeper, Manya
PY - 2017
Y1 - 2017
N2 - The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown. To identify genetic risk factors for and novel characteristics of secondary leukemia, we profiled 116 204 single nucleotide polymorphisms (SNPs) in germline and paired leukemic cell DNA from 13 secondary leukemia/myelodysplasia cases and germline DNA from 13 matched and 156 unmatched controls, all with acute lymphoblastic leukemia treated with etoposide. We analyzed global gene expression from a partially overlapping cohort. No single locus was altered in most cases. We discovered 81 regions of loss of heterozygosity (LOH) in leukemic blasts and 309 SNPs whose allele frequencies differed in cases vs controls. Candidate genes were prioritized on the basis of genes whose SNPs or expression differentiated cases from controls or showed LOH or copy number change in germline vs paired blast DNA from the13 cases. Three biological pathways were altered: adhesion, Wnt signaling and regulation of actin. Validation experiments using a genome scan for etoposide-induced leukemogenic MLL chimeric fusions in 15 HapMap cell lines also implicated genes involved in adhesion, a process linked to de novo leukemogenesis. Independent clinical epidemiologic and in vitro genome-wide approaches converged to identify novel pathways that may contribute to therapy-induced leukemia.Leukemia (2007) 21, 2128–2136; doi:10.1038/sj.leu.2404885; published online 2 August 2007 [ABSTRACT FROM AUTHOR]
AB - The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown. To identify genetic risk factors for and novel characteristics of secondary leukemia, we profiled 116 204 single nucleotide polymorphisms (SNPs) in germline and paired leukemic cell DNA from 13 secondary leukemia/myelodysplasia cases and germline DNA from 13 matched and 156 unmatched controls, all with acute lymphoblastic leukemia treated with etoposide. We analyzed global gene expression from a partially overlapping cohort. No single locus was altered in most cases. We discovered 81 regions of loss of heterozygosity (LOH) in leukemic blasts and 309 SNPs whose allele frequencies differed in cases vs controls. Candidate genes were prioritized on the basis of genes whose SNPs or expression differentiated cases from controls or showed LOH or copy number change in germline vs paired blast DNA from the13 cases. Three biological pathways were altered: adhesion, Wnt signaling and regulation of actin. Validation experiments using a genome scan for etoposide-induced leukemogenic MLL chimeric fusions in 15 HapMap cell lines also implicated genes involved in adhesion, a process linked to de novo leukemogenesis. Independent clinical epidemiologic and in vitro genome-wide approaches converged to identify novel pathways that may contribute to therapy-induced leukemia.Leukemia (2007) 21, 2128–2136; doi:10.1038/sj.leu.2404885; published online 2 August 2007 [ABSTRACT FROM AUTHOR]
UR - http://dx.doi.org/10.1145/3054926
UR - http://www.mendeley.com/research/nudges-privacy-security-understanding-assisting-users-choices-online-acm-reference-format
U2 - 10.1145/3054926
DO - 10.1145/3054926
M3 - Article
VL - 50
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 3
ER -